In addition, several studies have indicated that Ror1 might be ideal therapeutic target of cancers including leukemia and breast cancer (Karvonen et al., 2017; Choi et al., 2018; Wallstabe et al., 2019; Zhang et al., 2019; Stüber et al., 2020). Here, ROR1 is linked to breast carcinoma.